Skip to content

Daily News

47°F
Monday, January 12th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

1.999 -0.071 (-3.45%)
Streaming Delayed Price Updated: 11:05 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics 
From Neuronetics
Via GlobeNewswire
News headline image
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
From Neuronetics
Via GlobeNewswire
News headline image
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
Policy update increases access for millions covered by Evernorth Health Services 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Data selected for oral presentation reinforce previous findings on safety and efficacy 
From Neuronetics
Via GlobeNewswire
News headline image
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies 
From Neuronetics
Via GlobeNewswire
News headline image
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Releases Software Upgrades to Elevate Patient Care
Upgrades improve communication, streamline data management, and strengthen security 
From Neuronetics
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
New initiative aims to provide information and resources for teen mental health amidst rising public health concerns 
From Neuronetics
Via GlobeNewswire
News headline image
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
Coverage criteria consistent with recent FDA clearance for NeuroStar TMS 
From Neuronetics
Via GlobeNewswire
News headline image
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal 
From Neuronetics
Via GlobeNewswire
News headline image
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Launches Better Me Provider Program Nationwide
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 
From Neuronetics
Via GlobeNewswire
News headline image
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance 
From Neuronetics
Via GlobeNewswire
News headline image
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Lack of early symptom improvement is not predictive of final responder status 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
Advancements provide workflow efficiencies for NeuroStar® TMS providers 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
Criteria Change Reduces Requirements for Treatment Accessibility 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
Technological advances reduce time and increase efficiency for MDD treatment 
From Neuronetics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.